X4 Pharmaceuticals Inc Asset Resilience Ratio
X4 Pharmaceuticals Inc asset resilience ratio. X4 Pharmaceuticals Inc (XFOR) has an Asset Resilience Ratio of 5.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XFOR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of X4 Pharmaceuticals Inc (2022–2025)
Asset resilience ratio of X4 Pharmaceuticals Inc from 2022 to 2025. This chart shows how X4 Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read XFOR liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down X4 Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see X4 Pharmaceuticals Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.87 Million | 5.09% |
| Total Liquid Assets | $12.87 Million | 5.09% |
Asset Resilience Insights
- Limited Liquidity: X4 Pharmaceuticals Inc maintains only 5.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
X4 Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare X4 Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
X4 Pharmaceuticals Inc Asset Resilience Ratio by Year (2022–2025)
X4 Pharmaceuticals Inc asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for X4 Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.38% | $35.95 Million | $290.46 Million | -19.28pp |
| 2024-12-31 | 31.66% | $46.36 Million | $146.45 Million | +21.47pp |
| 2023-12-31 | 10.19% | $15.00 Million | $147.26 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $155.59 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more